Funding
← Back to your selection

Saras Capital

Activity from announced rounds

Activity in this selectionUndisclosed

Saras Capital is the investor linked by Biographica, Converge and Shennon sources to Nadav Rosenberg.

Recorded funding activity

Biographica develops crop traits using AI discovery. Converge supplies drug-discovery models, while Shennon develops cancer therapies. These company records preserve separate biological applications and financing events.

Sources
Rounds participated in
2
Confirmed lead rounds
0
1 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$21.4M
2 disclosed · full round size, not this investor’s share

By stage

Undisclosed2

By primary sector

Agritech1
Biotech1

By country

United Kingdom1
United States1

Rounds

2 in this selection
Shennon Biotechnologies

Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors.

$12MFunding
Participant
Biographica

Uses AI-driven discovery to develop next-generation crop traits and improve agricultural productivity and resilience

£7MUndisclosed
Role not disclosed